06/15/2012 On June 15, 2012, the U.S. District Court for the District of New Jersey issued a ruling finding that Apotex Inc.’s generic mometasone furoate nasal spray product does not infringe U.S. Patent No. 6,127,353. In the litigation, Schering Corporation sought to prevent Apotex’s marketing of a generic equivalent to Nasonex® (mometasone furoate). After a 7-day bench trial, the District Court concluded that Apotex’s generic mometasone furoate nasal spray product does not infringe the ‘353 patent.
This decision could have long-ranging impact in the pharmaceutical, chemical and biotechnology areas, and this victory continues to place RMMS at the forefront of generic challenges to brand pharmaceutical patents.
Deanne Mazzochi, Paul Molino, William Rakoczy, Andrew Alul, Roy Chamcharas, Matthew Anderson, and Yixin Tang tried the case for Apotex.